Pregnant women and their fetuses are increasingly likely to be exposed to
antipsychotics. However, safety data remain limited. This editorial suggests
that, in future, well-designed observational pharmaco-epidemiology is our
best chance of illuminating risk for exposed populations and of informing
decision-making for women and clinicians.